<![CDATA[EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression]]>

<![CDATA[In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase inhibitor and chemotherapy, now with new brain metastases.]]>

🔗 mentioned in this article

no entities indexed yet